Sign In
Buy FUSN
$13.26
+0 (+0%)
At Close: Sep 04, 2020
Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences
04:10pm, Tuesday, 05'th Sep 2023
HAMILTON, ON and BOSTON , Sept. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates
09:56am, Tuesday, 08'th Aug 2023
Fusion Pharmaceuticals Inc. (FUSN) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.44 per share a year ago.
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R
08:05am, Monday, 26'th Jun 2023
Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in
Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit
08:05am, Friday, 16'th Jun 2023
HAMILTON, ON and BOSTON , June 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec
Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
07:45am, Tuesday, 09'th May 2023
HAMILTON, ON and BOSTON , May 9, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
04:15pm, Thursday, 20'th Apr 2023
HAMILTON, ON and BOSTON , April 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre
Fusion Pharmaceuticals Inc. (FUSN) Reports Q4 Loss, Tops Revenue Estimates
09:56am, Thursday, 16'th Mar 2023
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 3.51% and 16.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
04:35pm, Thursday, 02'nd Mar 2023
HAMILTON, ON and BOSTON , March 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec
Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
08:05am, Monday, 13'th Feb 2023
HAMILTON, ON and BOSTON , Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
03:01pm, Wednesday, 30'th Nov 2022 Benzinga
Upgrades
For Avadel Pharmaceuticals PLC (NASDAQ:AVDL), Jefferies upgraded the previous rating of Hold to Buy. In the third quarter, Avadel Pharmaceuticals showed an EPS of $0.33, compared to $0.38 fro
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates
01:25pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates
09:47am, Tuesday, 08'th Nov 2022
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
09:35am, Friday, 21'st Oct 2022 Zacks Investment Research
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
03:26pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
5 Stocks to Bet on in an Innovation-Driven Drug Industry
02:31pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
